Home/Indications/Oncology/Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Oncology 9 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Oncology indication. Diffuse Large B-cell Lymphoma has 9 FDA-approved novel treatments, led by Roche across 6 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Diffuse Large B-cell Lymphoma Market Leaders

Companies with the most FDA-approved novel Diffuse Large B-cell Lymphoma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Tafasitamab

Incyte Corporation

Estimated · fresh NCT04824092

Q4 2026

Ibrutinib

Johnson & Johnson

Estimated · fresh NCT01804686

Q1 2027

Tazemetostat

Epizyme, Inc.

Estimated · fresh NCT04224493

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Diffuse Large B-cell Lymphoma Treatments by Mechanism

Top 12 mechanisms across 51 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

18 trials 4 active 8 sponsors

CD20-directed Cytolytic Antibody

9 trials 2 active 5 sponsors

CD19-directed Chimeric Antigen Receptor

7 trials 2 active 2 sponsors

DNA

3 trials 1 active 3 sponsors

CD30-directed Immunoconjugate

1 trials 1 active 1 sponsor

Nuclear Export Inhibitor

1 trials 1 active 1 sponsor

PI3K-delta/PI3K-gamma

3 trials 1 sponsor

Thalidomide Analog

2 trials 2 sponsors

CD20

2 trials 1 sponsor

BCL-2 Inhibitor

2 trials 2 sponsors

Proteasome Inhibitor

2 trials 1 sponsor

Programmed Death Ligand-1 Blocker

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Diffuse Large B-cell Lymphoma Clinical Pipeline by Phase

289 industry-sponsored trials across 136 sponsors

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2020-08-04	NCT03817853

Showing 62 of 62 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT01804686
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1912 Injection	—	RECRUITING	2027-03	NCT06929624
Novartis	CTL019	—	RECRUITING	2027-03-31	NCT04094311
Merck	Zilovertamab vedotin	—	RECRUITING	2027-09-24	NCT05139017
Regeneron	Odronextamab	—	RECRUITING	2028-02-07	NCT06091254
Bristol-Myers Squibb	Golcadomide	—	RECRUITING	2028-04-24	NCT06911502
BeOne Medicines	Zanubrutinib	Kinase Inhibitor [EPC]	RECRUITING	2028-07	NCT05100862
Beijing InnoCare Pharma Tech Co., Ltd.	Tafasitamab	—	RECRUITING	2028-09	NCT06521255
Regeneron	Odronextamab	—	RECRUITING	2029-01-23	NCT06149286
Merck	Zilovertamab vedotin	—	RECRUITING	2029-07-02	NCT06717347
AstraZeneca	Surovatamig	—	RECRUITING	2031-11-26	NCT06549595
Merck	MK-1045	—	RECRUITING	2032-07-23	NCT07634471
Genmab	Epcoritamab	—	RECRUITING	2037-11	NCT06191744
Beijing Mabworks Biotech Co., Ltd.	Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide	—	RECRUITING	2025-03	NCT04834024
Incyte Corporation	Tafasitamab	—	ACTIVE NOT RECRUITING	2026-09-01	NCT04824092
Epizyme, Inc.	Tazemetostat	—	ACTIVE NOT RECRUITING	2027-02-13	NCT04224493
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-02-22	NCT04529772
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-06	NCT05578976
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2028-03	NCT06508658
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2028-03-31	NCT04408638
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	ACTIVE NOT RECRUITING	2028-07-25	NCT05888493
Regeneron	Odronextamab	—	ACTIVE NOT RECRUITING	2029-07-29	NCT06097364
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2029-12	NCT05409066
Kite, A Gilead Company	Axicabtagene Ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	ACTIVE NOT RECRUITING	2030-10	NCT05371093
Roche	Mosunetuzumab	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04712097
Incyte Corporation	Tafasitamab	—	ACTIVE NOT RECRUITING	2026-03-30	NCT05429268
Seagen, a wholly owned subsidiary of Pfizer	Brentuximab vedotin	CD30-directed Immunoconjugate [EPC]	ACTIVE NOT RECRUITING	2026-01-12	NCT04404283
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT07226752
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT04628494
Incyte Corporation	tafasitamab	—	ACTIVE NOT RECRUITING	2024-02-23	NCT04680052
Sinocelltech Ltd.	SCTB35 injection	—	NOT YET RECRUITING	2028-05	NCT07562022
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQB2825 Injection	—	NOT YET RECRUITING	2028-10	NCT07187960
Roche	Polatuzumab Vedotin	—	COMPLETED	2026-04-30	NCT03274492
Roche	Polatuzumab Vedotin	—	COMPLETED	2024-11-29	NCT04182204
Incyte Corporation	Rituximab (RTX)	—	COMPLETED	2024-06-21	NCT02763319
Bristol-Myers Squibb	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-04-30	NCT01476787
Pharmacyclics LLC.	Ibrutinib Oral Capsule	—	COMPLETED	2024-02-21	NCT02947347
Chipscreen Biosciences, Ltd.	R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)	—	COMPLETED	2023-01-10	NCT04231448
Dr. Reddy's Laboratories Limited	DRL_RI (Proposed rituximab biosimilar)	—	COMPLETED	2022-09-28	NCT03976102
Denovo Biopharma LLC	Enzastaurin Hydrochloride	—	COMPLETED	2022-08-11	NCT03263026
Shanghai Institute Of Biological Products	SIBP-02	—	COMPLETED	2022-05-20	NCT04361279
CTI BioPharma	Pixantrone + Rituximab	—	COMPLETED	2018-06-28	NCT01321541
Celltrion	CT-P10	—	COMPLETED	2018-01-04	NCT02260804
Pfizer	PF-05280586	—	COMPLETED	2017-10-23	NCT02213263
Mabion SA	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-08	NCT02617485
Novartis	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2016-06-15	NCT00790036
mAbxience Research S.L.	RTXM83	—	COMPLETED	2016-05	NCT02268045
Novartis	GP2013	—	COMPLETED	2015-07-10	NCT01419665
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2013-07-04	NCT01197560
MEI Pharma, Inc.	Zandelisib	—	TERMINATED	2023-03-20	NCT04745832
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2022-09-27	NCT02536300
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-31	NCT02793583
Pfizer	Avelumab	Programmed Death Ligand-1 Blocker [EPC]	TERMINATED	2019-12-02	NCT02951156
JHL Biotech, Inc.	JHL1101	—	TERMINATED	2019-03-07	NCT03670901
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	TERMINATED	2016-12	NCT02204982
Roche	Rituximab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2016-04-29	NCT01287741
Spectrum Pharmaceuticals, Inc	Zevalin	CD20	TERMINATED	2014-10-23	NCT01510184
Spectrum Pharmaceuticals, Inc	Zevalin	CD20	TERMINATED	2013-03-05	NCT01662102
Incyte Corporation	parsaclisib	—	WITHDRAWN	2028-12-20	NCT04796922
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Cyclophosphamide	DNA	WITHDRAWN	2031-10-16	NCT06313996
Shanghai Henlius Biotech	HLX01	—	WITHDRAWN	2022-04	NCT04671420
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	WITHDRAWN	2016-11	NCT02576275

Showing 100 of 129 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
BeOne Medicines	BGB-16673	—	RECRUITING	2026-11	NCT05006716
Pell Bio-Med Technology Co., Ltd.	CD19-targeted chimeric antigen receptor T-cell	—	RECRUITING	2026-12-31	NCT05326243
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	RECRUITING	2027-01-31	NCT06806033
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
AstraZeneca	Surovatamig	—	RECRUITING	2027-11-24	NCT06526793
Evopoint Biosciences Inc.	XNW5004 tablets	—	RECRUITING	2027-12-31	NCT07545603
ModeX Therapeutics, An OPKO Health Company	MDX2003	—	RECRUITING	2028-01	NCT07249905
TICAROS Co., Ltd.	TC011	—	RECRUITING	2028-02-11	NCT07473167
Merck	Nemtabrutinib	—	RECRUITING	2029-01-04	NCT04728893
BeiGene	BGB-16673	—	RECRUITING	2029-01-31	NCT05294731
Merck	Zilovertamab vedotin	—	RECRUITING	2029-03-31	NCT06395103
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	RECRUITING	2029-04-22	NCT05952024
Enterome	EO2463	—	RECRUITING	2029-05-30	NCT04669171
CRISPR Therapeutics AG	CTX112	—	RECRUITING	2030-01	NCT05643742
Dizal Pharmaceuticals	DZD8586+R-CHOP	—	RECRUITING	2030-10	NCT07059650
Ascentage Pharma Group Inc.	APG-115	—	RECRUITING	2026-05-31	NCT04496349
Indapta Therapeutics, INC.	IDP-023	—	RECRUITING	2025-12-30	NCT06119685
Ranok Therapeutics (Hangzhou) Co., Ltd.	RNK05047	—	RECRUITING	2025-06-01	NCT05487170
Beijing InnoCare Pharma Tech Co., Ltd.	Tafasitamab and Lenalidomide	—	RECRUITING	2025-04	NCT05552937
Miltenyi Biomedicine GmbH	Standard of Care	—	RECRUITING	2025-01-15	NCT04844866
Beijing Mabworks Biotech Co., Ltd.	Recombinant Humanized Monoclonal Antibody MIL62 Injection	—	RECRUITING	2024-01-09	NCT04110301
Curocell Inc.	CRC01	—	RECRUITING	2023-05	NCT04836507
Beijing Immunochina Medical Science & Technology Co., Ltd.	IM19 CAR-T Cells	—	RECRUITING	2022-06-04	NCT04440436
Roche	Glofitamab	—	ACTIVE NOT RECRUITING	2026-10-16	NCT03533283
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12	NCT02227251
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-03	NCT05451810
Novartis	Rapcabtagene autoleucel single agent	—	ACTIVE NOT RECRUITING	2027-06-30	NCT03960840
Genmab	Epcoritamab (monotherapy)	—	ACTIVE NOT RECRUITING	2027-09	NCT04542824
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2027-09-17	NCT03162536
Genmab	rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone	—	ACTIVE NOT RECRUITING	2027-09-30	NCT04663347
Xynomic Pharmaceuticals, Inc.	Abexinostat	—	ACTIVE NOT RECRUITING	2027-12-31	NCT03600441
Tanabe Pharma Corporation	MT-2111	—	ACTIVE NOT RECRUITING	2028-08	NCT05658562
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2029-01	NCT03625037
Merck	Zilovertamab vedotin	—	ACTIVE NOT RECRUITING	2029-05-17	NCT05458297
Roche	Mosunetuzumab (IV)	—	ACTIVE NOT RECRUITING	2030-09-06	NCT04246086
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2026-06-14	NCT05660967
Monte Rosa Therapeutics, Inc	Oral MRT-2359	—	ACTIVE NOT RECRUITING	2026-05	NCT05546268
Immunitas Therapeutics	IMT-009	—	ACTIVE NOT RECRUITING	2026-01	NCT05565417
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-038	—	ACTIVE NOT RECRUITING	2025-12	NCT05192486
Incyte Biosciences Japan GK	tafasitamab	—	ACTIVE NOT RECRUITING	2025-07-01	NCT04661007
Shanghai Blueray Biopharma Co., Ltd.	BR1733	—	ACTIVE NOT RECRUITING	2025-05	NCT05749549
Shanghai Ming Ju Biotechnology Co., Ltd.	Relmacabtagene Autoleucel	—	ACTIVE NOT RECRUITING	2024-01-21	NCT06093841
Jiangsu HengRui Medicine Co., Ltd.	SHR2554	—	NOT YET RECRUITING	2027-04	NCT06368167
TICAROS Co., Ltd.	TC011 single-arm	—	NOT YET RECRUITING	2028-05-31	NCT07360288
Guangzhou Lupeng Pharmaceutical Company LTD.	Lacutoclax+Rocbrutinib	—	NOT YET RECRUITING	2029-06-30	NCT07609862
Innovent Biologics (Suzhou) Co. Ltd.	Sintilimab	—	NOT YET RECRUITING	2025-12-31	NCT05280626
XEME Biopharma Inc.	Oncoquest-L vaccine	—	NOT YET RECRUITING	2024-06	NCT02194751
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2025-09-26	NCT02875548
Roche	Mosunetuzumab Intravenous (IV)	—	COMPLETED	2025-08-07	NCT03677154
Kite, A Gilead Company	Axicabtagene ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2024-12-20	NCT03105336
Hutchmed	Tazemetostat	—	COMPLETED	2024-11-30	NCT05467943
Cyteir Therapeutics, Inc.	CYT-0851	—	COMPLETED	2024-11-30	NCT03997968
BeiGene	BGB-10188	—	COMPLETED	2024-08-28	NCT04282018
Hutchison Medipharma Limited	HMPL-689	—	COMPLETED	2024-02-29	NCT04849351
Kite, A Gilead Company	Axicabtagene Ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2023-07-27	NCT02348216
TCR2 Therapeutics	TC-110 T Cells	—	COMPLETED	2023-02-24	NCT04323657
MorphoSys AG	Tafasitamab	—	COMPLETED	2022-11-14	NCT02399085
Nordic Nanovector	10 MBq/kg Betalutin	—	COMPLETED	2022-10-25	NCT01796171
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2021-08-24	NCT01897571
Debiopharm International SA	Debio 1562	—	COMPLETED	2021-01-13	NCT02564744
AstraZeneca	Cerdulatinib	—	COMPLETED	2020-12-15	NCT01994382
Novartis	tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2020-11-24	NCT03568461
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-08-28	NCT03520920
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-07-14	NCT02362035
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-06-01	NCT02328014
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2019-05-24	NCT03145064
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2019-04-26	NCT01109069
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2018-05-02	NCT01282424
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2017-11	NCT02401048
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2017-11	NCT01980654
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-03-08	NCT01691898
Bristol-Myers Squibb	CC-223	—	COMPLETED	2016-11-15	NCT01177397
Novartis	HSC835	—	COMPLETED	2016-10-03	NCT01474681
Roche	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2016-09-27	NCT02187861
Sanofi	SAR3419	—	COMPLETED	2016-09	NCT01472887
Zhejiang Hisun Pharmaceutical Co. Ltd.	HS006+CHOP	—	COMPLETED	2016-08-12	NCT03485118
MedImmune LLC	MEDI-551 2 mg/kg	—	COMPLETED	2016-07-11	NCT01453205
Millennium Pharmaceuticals, Inc.	IXAZOMIB	—	COMPLETED	2016-06-01	NCT01939899
Ionis Pharmaceuticals, Inc.	IONIS-STAT3Rx	—	COMPLETED	2016-03-23	NCT01563302
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2015-08	NCT01306643
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-05	NCT01647971
Millennium Pharmaceuticals, Inc.	Alisertib (MLN8237)	—	COMPLETED	2015-02-05	NCT01397825
Amgen Research (Munich) GmbH	Blinatumomab	CD19/CD3	COMPLETED	2014-07	NCT01741792
AstraZeneca	Fostamatinib	—	COMPLETED	2013-10	NCT01499303
Pharmatech	bendamustine	—	COMPLETED	2013-08	NCT00831597
Sanofi	SAR3419	—	COMPLETED	2013-07	NCT01470456
Gilead	veltuzumab	—	COMPLETED	2013-03	NCT00546793
Millennium Pharmaceuticals, Inc.	VELCADE	Proteasome Inhibitor [EPC]	COMPLETED	2012-06	NCT01040871
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2011-10	NCT01118845
Millennium Pharmaceuticals, Inc.	rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2011-02	NCT00715208
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2011-01-04	NCT00807495
Millennium Pharmaceuticals, Inc.	VELCADE	Proteasome Inhibitor [EPC]	COMPLETED	2010-05	NCT00636792
Pfizer	maplirpacept (PF-07901801)	—	TERMINATED	2026-04-09	NCT05896163
Antengene Corporation	ATG-010	—	TERMINATED	2024-12-31	NCT05265975
Zhejiang DTRM Biopharma	DTRM-555	—	TERMINATED	2024-12-31	NCT04305444
Pfizer	Maplirpacept	—	TERMINATED	2024-08-12	NCT05626322
IGM Biosciences, Inc.	imvotamab	—	TERMINATED	2024-02-16	NCT04082936
ADC Therapeutics S.A.	Loncastuximab Tesirine	—	TERMINATED	2024-01-22	NCT05144009
BioNova Pharmaceuticals (Shanghai) LTD.	BN301	—	TERMINATED	2023-12-25	NCT05611853
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT05720052

Showing 97 of 97 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Iksuda Therapeutics Ltd.	IKS03	—	RECRUITING	2026-09	NCT05365659
ADC Therapeutics S.A.	Loncastuximab Tesirine	—	RECRUITING	2026-12	NCT05660395
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2027-01	NCT05131022
AbbVie	ABBV-319	—	RECRUITING	2027-02	NCT05512390
GenomeFrontier Therapeutics TW Co., Ltd.	GF-CART01	—	RECRUITING	2027-03	NCT06703892
Eli Lilly	LY4584180	—	RECRUITING	2027-04	NCT07226843
Carna Biosciences, Inc.	Docirbrutinib	—	RECRUITING	2027-09	NCT05602363
Schrödinger, Inc.	SGR-1505	—	RECRUITING	2027-11	NCT05544019
Haisco Pharmaceutical Group Co., Ltd.	HSK47977	—	RECRUITING	2027-12	NCT07283796
Newave Pharmaceutical Inc	LP-168	—	RECRUITING	2027-12-31	NCT04775745
LTZ Therapeutics, Inc.	LTZ-301	—	RECRUITING	2028-02	NCT07121946
Pfizer	Mervometostat (PF-06821497)	—	RECRUITING	2028-04-20	NCT03460977
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS73565	—	RECRUITING	2028-06	NCT06980116
Verismo Therapeutics	SynKIR-310	—	RECRUITING	2028-09	NCT06544265
Regeneron	Odronextamab	—	RECRUITING	2029-02-16	NCT05685173
Nurix Therapeutics, Inc.	NX-2127	—	RECRUITING	2026-05	NCT04830137
OncoNano Medicine, Inc.	ONM-501	—	RECRUITING	2026-04-30	NCT06022029
Shanghai Exuma Biotechnology Ltd.	C402-CD19-CAR	—	RECRUITING	2026-03-09	NCT06830031
Chengdu FenDi Pharmaceutical Co., Ltd.	FD-001	—	RECRUITING	2026-01-24	NCT06731699
Cullinan Therapeutics Inc.	CLN-978	—	ACTIVE NOT RECRUITING	2026-11	NCT05879744
AstraZeneca	AZD0486 IV	—	ACTIVE NOT RECRUITING	2028-06-19	NCT04594642
Poseida Therapeutics, Inc.	P-CD19CD20-ALLO1	—	ACTIVE NOT RECRUITING	2029-03	NCT06014762
AbbVie	ABBV-525	—	ACTIVE NOT RECRUITING	2029-07	NCT05618028
Acepodia Biotech, Inc.	Cyclophosphamide	DNA	ACTIVE NOT RECRUITING	2026-07	NCT05653271
Synthekine	SYNCAR-001	—	ACTIVE NOT RECRUITING	2026-06-24	NCT05665062
BeOne Medicines	BGB-21447	—	ACTIVE NOT RECRUITING	2026-05	NCT05828589
Bio-Path Holdings, Inc.	L-Bcl-2 antisense oligonucleotide	—	ACTIVE NOT RECRUITING	2025-04	NCT04072458
Guangzhou Lupeng Pharmaceutical Company LTD.	Rocbrutinib	—	NOT YET RECRUITING	2027-12-31	NCT07570017
Ascentage Pharma Group Inc.	APG-3288	—	NOT YET RECRUITING	2029-12	NCT07424833
Boston Immune Technologies and Therapeutics	BITR2101	—	NOT YET RECRUITING	2026-06	NCT06385522
Juno Therapeutics, a Subsidiary of Celgene	JCAR017 (lisocabtagene maraleucel) single-dose schedule	—	COMPLETED	2024-05-16	NCT02631044
Xencor, Inc.	XmAb13676	—	COMPLETED	2024-04	NCT02924402
Sutro Biopharma, Inc.	STRO-001	—	COMPLETED	2024-02-15	NCT03424603
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Zilovertamab vedotin	—	COMPLETED	2023-12-18	NCT03833180
Boryung Pharmaceutical Co., Ltd	BR101801 (Phase Ia)	—	COMPLETED	2023-09-21	NCT04018248
Kymera Therapeutics, Inc.	KT-413	—	COMPLETED	2023-07-28	NCT05233033
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2023-04-03	NCT04537715
Celldex Therapeutics	CDX-1140	—	COMPLETED	2022-09-13	NCT03329950
Nordic Nanovector	10 MBq/kg Betalutin	—	COMPLETED	2022-08-08	NCT03806179
Allogene Therapeutics	ALLO-647	—	COMPLETED	2021-10-23	NCT03939026
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2021-07-20	NCT03630159
Opna Bio LLC	PLX2853	—	COMPLETED	2021-06-07	NCT03297424
Acerta Pharma BV	AZD9150	—	COMPLETED	2021-03-31	NCT03527147
MorphoSys AG	Tafasitamab	—	COMPLETED	2021-02-11	NCT04134936
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-06-26	NCT01953692
MedImmune LLC	MEDI7247	—	COMPLETED	2020-01-03	NCT03106428
AbbVie	ABBV-075	—	COMPLETED	2019-07-05	NCT02391480
Roche	RO6870810	—	COMPLETED	2019-07-03	NCT03255096
MedImmune LLC	MEDI4736	—	COMPLETED	2019-02-04	NCT02549651
Epizyme, Inc.	Tazemetostat and [14C] Tazemetostat	—	COMPLETED	2019-01-08	NCT03010982
Novartis	BCL201	—	COMPLETED	2018-07-10	NCT02603445
Seagen Inc.	SGN-CD70A	—	COMPLETED	2017-02-15	NCT02216890
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	OTX015/Birabresib	—	COMPLETED	2017-01-20	NCT01713582
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2016-10-01	NCT00697346
Morphotek	anti-endosialin/TEM1 monoclonal antibody MORAb-004	—	COMPLETED	2015-05	NCT01748721
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2014-12-25	NCT02242045
Bristol-Myers Squibb	BMS-936564 (Anti-CXCR4)	—	COMPLETED	2014-11	NCT01120457
Teva Branded Pharmaceutical Products R&D, Inc.	TL011	—	COMPLETED	2013-07	NCT01205737
Millennium Pharmaceuticals, Inc.	TAK-901	—	COMPLETED	2012-09	NCT00807677
Roche	Polatuzumab Vedotin	—	COMPLETED	2012-06-29	NCT01290549
Novartis	HCD122	—	COMPLETED	2012-05	NCT01275209
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2010-03	NCT00794638
Pfizer	PF-08046032	—	TERMINATED	2026-04-23	NCT06870487
Novartis	MAK683	—	TERMINATED	2024-10-09	NCT02900651
Novartis	JBH492	—	TERMINATED	2024-09-05	NCT04240704
MEI Pharma, Inc.	voruciclib monotherapy	—	TERMINATED	2024-07-24	NCT03547115
Pfizer	Maplirpacept (PF-07901801)	—	TERMINATED	2024-07-18	NCT03530683
TG Therapeutics, Inc.	TG-1801	—	TERMINATED	2024-06-12	NCT04806035
Epizyme, Inc.	EZM0414	—	TERMINATED	2024-04-30	NCT05121103
Prelude Therapeutics	PRT1419	—	TERMINATED	2024-01-19	NCT05107856
Seagen Inc.	SEA-TGT	—	TERMINATED	2023-12-01	NCT04254107
Shengke Pharmaceuticals Pty Ltd	ETH-155008	—	TERMINATED	2023-05-02	NCT04840784
MEI Pharma, Inc.	ME-401	—	TERMINATED	2023-03-29	NCT02914938
Eden BioCell Ltd.	RPM CD19-mbIL15-CAR-T cells	—	TERMINATED	2022-05-12	NCT04844086
Amgen	AMG 562	—	TERMINATED	2022-01-12	NCT03571828
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	TERMINATED	2021-11-01	NCT03876028
Karyopharm Therapeutics Inc	KPT-9274	—	TERMINATED	2021-01-26	NCT02702492
ADC Therapeutics S.A.	Loncastuximab Tesirine and Durvalumab	—	TERMINATED	2020-10-27	NCT03685344
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	TERMINATED	2019-12-30	NCT03797261
Amgen	AMG 397	—	TERMINATED	2019-07-25	NCT03465540
Seagen Inc.	SGN-CD19B	—	TERMINATED	2018-07-10	NCT02702141
Merck	Birabresib Dose 20 mg	—	TERMINATED	2018-01-18	NCT02698189
Gilead	IMMU-114	—	TERMINATED	2017-03	NCT01728207
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	DCR-MYC	—	TERMINATED	2016-10-05	NCT02110563
Gilead	GS-9901	—	TERMINATED	2015-08	NCT02258555
Merck	MK-8808	—	TERMINATED	2014-12-01	NCT01370694
Novartis	AEB071	—	TERMINATED	2014-04	NCT01402440
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2014-02-07	NCT01744912
Celltrion	rituximab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2013-02	NCT01534949
Astex Pharmaceuticals, Inc.	SGI-1776	—	TERMINATED	2010-10	NCT00848601
Innovent Biologics (Suzhou) Co. Ltd.	lenalidomide	Thalidomide Analog [EPC]	WITHDRAWN	2029-08-31	NCT05867030
Fate Therapeutics	FT596	—	WITHDRAWN	2026-05	NCT05934097
Spectrum Pharmaceuticals, Inc	IGN002	—	WITHDRAWN	2025-07	NCT02847949
ADC Therapeutics S.A.	Loncastuximab tesirine	—	WITHDRAWN	2024-03-11	NCT04974996
Hutchmed	HMPL-760	—	WITHDRAWN	2022-11-16	NCT05176691
Gilead	Idelalisib	Kinase Inhibitor [EPC]	WITHDRAWN	2021-02	NCT03349346

Novel Diffuse Large B-cell Lymphoma Drugs by Company (New molecular entities)

8 companies have an FDA-approved novel drug for Diffuse Large B-cell Lymphoma.

Roche 2 drugs

GENMAB US, INC. 1 drug

EPKINLY

EPCORITAMAB-BYSP

BLA 2023

SEATTLE GENETICS 1 drug

ADCETRIS

BRENTUXIMAB VEDOTIN

BLA 2011

KARYOPHARM THERAPS 1 drug

XPOVIO

SELINEXOR

NDA 2019

ADC Therapeutics SA 1 drug

ZYNLONTA

LONCASTUXIMAB TESIRINE-LPYL

BLA 2021

MORPHOSYS US INC 1 drug

Novartis 1 drug

Juno Therapeutics, Inc. a Bristol Myer-Squibb Company 1 drug

Breyanzi

lisocabtagene maraleucel

BLA 2021

Reformulations (1 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

RITUXAN HYCELA

Roche

T5 2017

Diffuse Large B-cell Lymphoma Drug Targets

Molecular targets of approved and investigational Diffuse Large B-cell Lymphoma drugs — 6 targets tracked.

CD20 7 CD19 4 CD3 2 Hyaluronan 1 CD30 1 XPO1 1

Biosimilars (3 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

2018

Related Indications

Other Oncology indications

View all Oncology

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology